<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00918268</url>
  </required_header>
  <id_info>
    <org_study_id>V71_10S</org_study_id>
    <secondary_id>2009−010598−19</secondary_id>
    <nct_id>NCT00918268</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine Using the Strain Composition 2009/2010 Recommended in Northern Hemisphere in Non-elderly Adult and in Elderly Subjects</brief_title>
  <official_title>A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2009-2010, When Administered to Non-elderly Adult and Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Annual trial for registration influenza vaccine with the strain composition for season
      2009/2010.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the antibody response to each influenza vaccine antigen, as measured by Single Radial Hemolysis (SRH) at 21 days post-immunization in non-elderly adult and elderly subjects</measure>
    <time_frame>21(-1/+5) days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of safety of a single intramuscular injection of influenza vaccine in non elderly adult and elderly subjects</measure>
    <time_frame>21(-1/+5) days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Influenza Disease</condition>
  <arm_group>
    <arm_group_label>Influenza vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza vaccine</intervention_name>
    <description>One 0.5mL dose of Inactivated, Influenza Vaccine using the strain composition 2009/2010</description>
    <arm_group_label>Influenza vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older, mentally competent, willing and able to give written
             informed consent prior to study entry;

          -  able to comply with all the study requirements;

          -  in general good health as determined by:medical history, physical examination and-
             clinical judgment of the investigator Written informed consent must be obtained for
             all the subjects before enrollment into the study after the nature of the study has
             been explained.

        Exclusion Criteria:

          -  They have any serious chronic or acute disease (in the judgment of the investigator)
             including but not limited to:

               1. Cancer, except for localized skin cancer;

               2. Advanced congestive heart failure

               3. Chronic obstructive pulmonary disease (COPD);

               4. Autoimmune disease (including rheumatoid arthritis);

               5. Acute or progressive hepatic disease;

               6. Acute or progressive renal disease;

               7. Severe neurological or psychiatric disorder

               8. Severe asthma

          -  They have history of any anaphylactic reaction and/or serious allergic reaction
             following a vaccination, a proven hypersensitivity to any component of the study
             vaccine (e.g., to ovalbumin, chicken protein, chicken feathers, influenza viral
             protein, kanamycin and neomycin sulphate);

          -  They have a known or suspected (or have a high risk of developing)
             impairment/alteration of immune function (excluding that normally associated with
             advanced age) resulting, for example, from:- receipt of immunosuppressive therapy (any
             parenteral or oral corticosteroid or cancer chemotherapy/radiotherapy) within the past
             60 days and for the full length of the study;receipt of immunostimulants,receipt of
             parenteral immunoglobulin preparation, blood products and/or plasma derivates within
             the past 3 months and for the full length of the study and suspected or known HIV
             infection or HIV-related disease;

          -  They have a known or suspected history of drug or alcohol abuse;

          -  They have a bleeding diathesis or condition associated with prolonged bleeding time
             that in the investigator's opinion would interfere with the safety of the subject;

          -  Female who are pregnant or nursing (breastfeeding) mothers or females of childbearing
             age do not plan to use acceptable birth control measures, for the duration of the
             study. Adequate contraception is defined as hormonal (e.g., oral, injection,
             transdermal patch, implant, cervical ring), barrier (e.g., condom or diaphragm),
             intrauterine device (IUD), or monogamous relationship with vasectomized partner who
             has been vasectomized for 6 months or more prior to the subject's study entry;

          -  Within the past 12 months, they have:- received more than one injection of influenza
             vaccine

          -  Within the past 6 months, they have:-had laboratory confirmed influenza disease,-
             received influenza vaccine;

          -  Within the past 4 weeks they have received:-another vaccine;-any investigational
             agent;

          -  They have any acute or chronic infection requiring systemic antibiotic treatment or
             antiviral therapy within the last 7 days;

          -  They have experienced fever (i.e., axillary temperature≥ 38°C) within the last 3 days;

          -  They are taking part in another clinical study;

          -  They have any condition which, in the opinion of the investigator,might interfere with
             the evaluation of the study objectives;

          -  They are severely obese with Body Mass Index (BMI) &gt; 35;

          -  Site personnel involved in the evaluation of safety and their immediate relatives are
             excluded from participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dipartimento di Medicina e Scienze dell'Invecchiamento, Università G. D'Annunzio, Via dei Vestini</name>
      <address>
        <city>Chieti</city>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ufficio Igiene e Sanità Pubblica di Lanciano, ASL Lanciano - Vasto, sede legale Via S. Spaventa, 37 ----- Satellite sites: (a) Distretto Sanitario di Base, Via Don Minzoni, Lanciano (CH) and (b) Distretto Sanitario di Base, Via Polidoro, Fossacesia (CH))</name>
      <address>
        <city>Lanciano</city>
        <zip>66034</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pianiga Distretto n. 2 - Area Sud - Azienda ULSS 13 Mirano-Via Nazionale 48</name>
      <address>
        <city>Pianiga</city>
        <zip>30030</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2009</study_first_submitted>
  <study_first_submitted_qc>June 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2009</study_first_posted>
  <last_update_submitted>April 20, 2012</last_update_submitted>
  <last_update_submitted_qc>April 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

